Studies on invivoandbiodistribution perspectives of solid lipid nanoparticles encompass isoniazid in animal model

Abstract

TB is an infectious disease caused by the bacillus Mycobacterium tuberculosis. It typically affects the lungs (pulmonary TB) but can affect other sites as well (extra pulmonary TB). The disease is spread in the air when people who are sick with pulmonary TB expel bacteria, for example by coughing. InvivoBiodistribution studies which was carried for the best formulation shows that, FS3 Isoniazid Solid lipid nanoparticle accumulates maximum dose of Isoniazid in the lungs than other organs over prolonged period of time by enhanced Cmax which confirmed that inhalable SLN are suitable for targeting and providing sustained release of anti-tubercular drugs to lungs. So Inhalation is an selected administration route of Isoniazid SLN.From the invivo screening of M.tuberculosis, its good activity in vivo models, as well as its activity against multidrug-resistant M. tuberculosis and against M. tuberculosis isolates in a potentially latent state, makes Isoniazid SLN an attractive drug dosage form for the therapy of tuberculosis.These data indicate that there is significant potential for effective oral delivery of Isoniazid SLN for the treatment of tuberculosis.